Hudson Bay Capital Management
EUCRW

Hudson Bay Capital Management’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Hudson Bay Capital Management’s Portfolio EUCRW Stock Details EUCRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-24,536
Closed -$1K – 1220
2022
Q3 		$1K Sell
24,536
-1,846
-7% -$117 ﹤0.01% 1211
2022
Q2 		$2K Hold
26,382
– – ﹤0.01% 1313
2022
Q1 		$5K Buy
+26,382
New +$10.7K ﹤0.01% 1171

Other funds holding EUCRW

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Hudson Bay Capital Management's EUCRW Position: Q4 2022 in Review

Hudson Bay Capital Management sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q4 2022, closing a stake of 24,536 shares — an estimated $1K sold.

Hudson Bay Capital Management first reported a position in EUCRW in Q1 2022 and held it in 3 quarters. The position peaked at $5K in Q1 2022. 25 funds tracked by Wall St. Rank hold EUCRW as of Q4 2022.

  • Hudson Bay Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q4 2022 after selling out during the quarter.
  • Hudson Bay Capital Management sold 24,536 Eucrates Biomedical Acquisition Corp. Warrant shares in Q4 2022, an estimated $1K.
  • Hudson Bay Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2022 and held it in 3 quarters.
  • Hudson Bay Capital Management's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $5K in Q1 2022.
  • 25 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q4 2022.

Based on Hudson Bay Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.